XORTX Therapeutics Inc. (NASDAQ:XRTX)
| Market Cap | 392.67K-68.9% |
| Revenue (ttm) | 0 |
| Net Income | -3.75M-98.9% |
| EPS | -2.74-45.0% |
| Shares Out | 278.49K |
| PE Ratio | n/a |
| Forward PE | 0.35 |
| Dividend | n/a |
| Ex-Dividend Date | Jan 31, 2014 |
| Volume | 17,149,254 |
| Open | 2.06 |
| Previous Close | 1.85 |
| Day's Range | 1.36 - 2.29 |
| 52-Week Range | 1.36 - 7.05 |
| Beta | 0.08 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 12, 2026 |
No insider has filed an open-market purchase or sale here in the last 90 days, so there is nothing to score yet.
About XRTX
XORTX Therapeutics Inc. is a biopharmaceutical firm dedicated to advancing and bringing to market medical treatments targeting a range of conditions, including chronic kidney ailments, diabetes, insulin resistance, metabolic syndrome, diabetic nephropathy, and various infections. Their pipeline includes XRx-008, a late-stage clinical program designed to address autosomal dominant polycystic kidney disease (ADPKD). Another key candidate is XRx-101, an agent aimed at reducing uric acid levels in COVID-19 patients, with the goal of mitigating acute kidney injury and related complications. Furthermore, they are developing XRx-221, a series of xanthine oxidase inhibitors intended for the management of diabetic nephropathy. XORTX also collaborates with the Icahn School of Medicine on research investigating acute kidney injury and hyperuricemia among hospitalized COVID-19 patients. The company's operations are headquartered in Vancouver, Canada.
$XRTX stock is featured in our Insider Trades datasets.
→ All Stock ListsRecently reported changes in XRTX holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by XRTX's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
XRTX Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New XRTX patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to XRTX from public contracts
Source: USAspending.gov
XRTX Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from XRTX’s recent data — informational, not investment advice
Recent Insider Activity
No Form 4 filings in the last 90 days.